Ascentage Pharma Group International announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation (the public notice period of which ended on July 18, 2022) to a new drug application (NDA) that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs).